Natalizumab induction and maintenance therapy for Crohn's disease
Sandborn WJ,
Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts for the International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Groups and the Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Groups.N Engl J Med.2005:
3531912-24
Help